These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 33139294)

  • 1. Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis.
    Panjasawatwong N; Wattanakul T; Hoglund RM; Bang ND; Pouplin T; Nosoongnoen W; Ngo VN; Day JN; Tarning J
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.
    Pouplin T; Bang ND; Toi PV; Phuong PN; Dung NH; Duong TN; Caws M; Thwaites GE; Tarning J; Day JN
    BMC Infect Dis; 2016 Apr; 16():144. PubMed ID: 27039088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.
    Savic RM; Ruslami R; Hibma JE; Hesseling A; Ramachandran G; Ganiem AR; Swaminathan S; McIlleron H; Gupta A; Thakur K; van Crevel R; Aarnoutse R; Dooley KE
    Clin Pharmacol Ther; 2015 Dec; 98(6):622-9. PubMed ID: 26260983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
    Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
    Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.
    Donald PR
    Tuberculosis (Edinb); 2010 Sep; 90(5):279-92. PubMed ID: 20709598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
    Van Schalkwyk M; Bekker A; Decloedt E; Wang J; Theron GB; Cotton MF; Eke AC; Cressey TR; Shapiro DE; Bacon K; Knowles K; George K; Browning R; Chakhtoura N; Rungruengthanakit K; Wiesner L; Capparelli EV; Stek AM; Mirochnick M; Best BM;
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0073723. PubMed ID: 37882552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
    Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
    Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chemotherapy of tuberculous meningitis in children and adults.
    Donald PR
    Tuberculosis (Edinb); 2010 Nov; 90(6):375-92. PubMed ID: 20810322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of first-line anti-tuberculosis drugs combined with Linezolid for the treatment of pediatric tuberculous meningitis in real-word practice].
    Ai T; Jiang L; Liu QB; Bai Y; Yang Y; Sun FJ; Jia YT; Zhou YJ; Zhang ZZ
    Zhonghua Er Ke Za Zhi; 2024 Aug; 62(8):715-720. PubMed ID: 39039872
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
    van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children.
    Thwaites G; Fisher M; Hemingway C; Scott G; Solomon T; Innes J;
    J Infect; 2009 Sep; 59(3):167-87. PubMed ID: 19643501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of tuberculous meningitis complicated with multiple drug hypersensitivity to antituberculosis agents].
    Arai M
    Rinsho Shinkeigaku; 2015; 55(2):123-5. PubMed ID: 25746078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
    Thwaites GE; Bhavnani SM; Chau TT; Hammel JP; Török ME; Van Wart SA; Mai PP; Reynolds DK; Caws M; Dung NT; Hien TT; Kulawy R; Farrar J; Ambrose PG
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3244-53. PubMed ID: 21502621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of additional levofloxacin in tuberculous meningitis: A randomized controlled pilot study.
    Kalita J; Bhoi SK; Betai S; Misra UK
    Tuberculosis (Edinb); 2016 May; 98():1-6. PubMed ID: 27156611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.
    Heemskerk D; Day J; Chau TT; Dung NH; Yen NT; Bang ND; Merson L; Olliaro P; Pouplin T; Caws M; Wolbers M; Farrar J
    Trials; 2011 Feb; 12():25. PubMed ID: 21288325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.